Study Overview: This is a Phase 1/2a study to find out if a new drug called CCS1477 (also known as inobrodib) is safe and how well it works in patients with blood cancers. These cancers include Non-Hodgkin Lymphoma, Multiple Myeloma, Acute Myeloid Leukemia, and High-Risk Myelodysplastic Syndrome. The study is also open to patients with Peripheral T-cell lymphoma.
Eligibility: To join, patients must consent to participate, have a good physical condition (ECOG 0-2), and have already tried standard cancer treatments. Patients should have normal organ function. Patients cannot join if they have had recent surgeries or taken certain drugs within a few weeks, have severe diseases, or have heart issues.
- Study Length: The duration of participation is not specified, but it is critical to discuss it with the study team.
- Visits: Regular visits to the study center may be required to monitor safety and effectiveness.
- Risks: As with any clinical trial, there may be risks and side effects. Participants should talk to their doctors about these risks.
How understandable was the trial content above?
Hard to understand
Easy to understand